activ
mutat
phosphoinositid
signal
pathway
frequent
identifi
cancer
identifi
pathway
support
oncogenesi
perform
genomewid
rnai
screen
isogen
cell
line
harbor
wildtyp
mutant
search
syntheticleth
sl
gene
combin
analysi
result
metaanalysi
two
largescal
rnai
screen
data
set
mutant
cancer
cell
line
converg
ribosom
protein
translat
proteasom
protein
degrad
critic
nononcogen
depend
tumor
genet
pharmacolog
inhibit
either
pathway
alon
togeth
select
kill
mutant
tumor
cell
mtordepend
manner
express
ribosom
proteasom
compon
significantli
upregul
primari
human
colorect
tumor
harbor
pathway
activ
importantli
sl
gene
signatur
contain
top
hit
sl
gene
identifi
metaanalysi
robustli
predict
overal
patient
surviv
colorect
cancer
especi
among
patient
tumor
activ
pathway
result
suggest
disrupt
protein
turnov
homeostasi
via
ribosom
proteasom
inhibit
may
novel
treatment
strategi
mutant
human
tumor
activ
mutat
phosphoinositid
signal
pathway
frequent
identifi
cancer
identifi
pathway
support
oncogenesi
perform
genomewid
rnai
screen
isogen
cell
line
harbor
wildtyp
mutant
search
syntheticleth
sl
gene
combin
analysi
result
metaanalysi
two
largescal
rnai
screen
data
set
mutant
cancer
cell
line
converg
ribosom
protein
translat
proteasom
protein
degrad
critic
nononcogen
depend
tumor
genet
pharmacolog
inhibit
either
pathway
alon
togeth
select
kill
mutant
tumor
cell
mtordepend
manner
express
ribosom
proteasom
compon
significantli
upregul
primari
human
colorect
tumor
harbor
pathway
activ
importantli
sl
gene
signatur
contain
top
hit
sl
gene
identifi
metaanalysi
robustli
predict
overal
patient
surviv
colorect
cancer
especi
among
patient
tumor
activ
pathway
result
suggest
disrupt
protein
turnov
homeostasi
via
ribosom
proteasom
inhibit
may
novel
treatment
strategi
mutant
human
tumor
keyword
genet
screen
synthet
lethal
supplement
materi
avail
articl
receiv
august
revis
version
accept
decemb
devis
strategi
select
kill
cancer
cell
spare
wildtyp
counterpart
persist
challeng
cancer
drug
develop
engelman
select
achiev
target
oncogen
driver
mutat
upon
cancer
cell
becom
depend
growth
surviv
jonker
bern
joe
exampl
tyrosin
kinas
tk
inhibitor
initi
efficaci
treat
tumor
harbor
oncogen
receptor
tk
rtk
mutat
paez
et
al
howev
mani
tumor
ultim
becom
resist
drug
linard
et
al
altern
approach
search
gene
exhibit
synthet
lethal
oncogen
mutat
fece
de
la
cruz
et
al
approach
base
concept
nononcogen
addict
postul
tumorigen
mutat
confer
certain
critic
cellular
depend
activ
specif
gene
oncogen
requir
greater
extent
cell
growth
surviv
tumor
cell
rel
wildtyp
cell
solimini
et
al
luo
et
al
concept
broaden
list
potenti
therapeut
target
beyond
oncogen
rnai
screen
use
extens
identif
nononcogen
addict
although
util
approach
often
hinder
ineffici
offtarget
effect
reagent
adamson
et
al
mohr
et
al
phosphoinositid
intracellular
lipid
kinas
phosphoryl
hydroxyl
posit
inositol
ring
phosphotidylinositol
ptdin
lead
activ
kinas
central
regul
cell
growth
whitman
et
al
key
downstream
transduc
pathway
serinethreonin
kinas
mtor
whose
activ
promot
protein
synthesi
anabol
process
yuan
cantley
mtor
stimul
translat
specif
mrna
contain
highli
structur
untransl
region
utr
oligopyrimidin
tract
mrna
encod
cell
cycl
regul
cyclin
myc
translat
factor
accomplish
primarili
phosphoryl
kinas
enhanc
translat
phosphorylationdepend
inhibit
neg
regul
translat
furthermor
promot
phosphoryl
transcript
factor
ubf
mtor
increas
rate
rdna
synthesi
hannan
et
al
recent
mtor
implic
promot
transcript
proteasom
gene
zhang
et
al
encod
catalyt
subunit
activ
hot
spot
mutat
helic
domain
kinas
domain
chalhoub
baker
found
colon
prostat
breast
cancer
among
other
samuel
velculescu
chalhoub
baker
constitut
activ
cancer
also
occur
secondari
pten
inactiv
rtkactiv
mutat
amplif
yuan
cantley
colorect
cancer
mutat
like
occur
transform
colon
polyp
malign
lesion
associ
poor
clinic
outcom
engelman
et
al
given
preval
import
mutat
human
cancer
number
isoformspecif
inhibitor
includ
inhibitor
dual
inhibitor
develop
drug
variou
phase
clinic
trial
wong
et
al
klempner
et
al
howev
contrast
effect
target
inhibitor
exampl
oncogen
addict
brcabl
egfr
mutat
singleag
pathway
inhibitor
thu
far
compar
success
luo
et
al
engelman
klempner
et
al
preclin
studi
mani
drug
led
tumor
stasi
rather
cell
death
vivo
substanti
tumor
shrinkag
observ
raynaud
et
al
serra
et
al
interestingli
combin
mek
inhibit
dual
inhibit
synergist
effect
lung
adenocarcinoma
engelman
et
al
activ
normal
develop
like
part
highli
coordin
process
cell
prolifer
growth
control
mutat
activ
outsid
normal
regulatori
environ
like
profound
possibl
unbalanc
effect
cellular
physiolog
could
produc
novel
vulner
tumor
identifi
specif
vulner
mutant
tumor
investig
genet
depend
human
cancer
cell
bear
oncogen
mutat
metaanalysi
genomewid
rnai
synthet
lethal
screen
isogen
colon
cancer
cell
larg
data
set
rnaibas
screen
cancer
cell
line
oncogen
mutat
uncov
particular
sensit
human
cancer
cell
oncogen
hyperactiv
inhibit
ribosom
protein
translat
proteasom
protein
degrad
use
gene
express
data
set
cancer
cell
line
human
primari
tumor
demonstr
multipl
molecular
compon
translat
pathway
proteasom
upregul
tumor
bear
mutat
importantli
gene
express
signatur
deriv
metaanalysi
syntheticleth
sl
interact
significantli
predict
overal
surviv
colorect
cancer
patient
result
suggest
disrupt
protein
turnov
homeostasi
via
ribosom
proteasom
inhibit
may
effect
treatment
strategi
mutant
human
tumor
genomewid
screen
gene
exhibit
synthet
lethal
oncogen
genomewid
shrna
screen
perform
pair
isogen
colon
cancer
cell
line
harbor
either
oncogen
mutat
mut
wildtyp
samuel
et
al
line
deriv
parent
line
inactiv
either
wildtyp
mut
allel
samuel
et
al
mut
wildtyp
cell
transduc
retrovir
shrna
librari
target
human
gene
four
shrna
per
gene
passag
eight
popul
doubl
rel
distribut
shrna
cell
popul
determin
nextgener
sequenc
ng
pcramplifi
halfhairpin
describ
previous
fig
determin
vulner
associ
mutat
first
use
edger
robinson
et
al
estim
lethal
score
ie
quantif
decreas
fit
shrna
separ
wildtyp
mut
cell
line
supplement
fig
edgerbas
method
ngsbase
genet
screen
superior
simpl
use
log
fold
chang
shrna
abund
compar
end
point
versu
start
point
quantifi
fit
chang
determin
reagent
genet
librari
see
materi
method
final
riger
rnai
gene
enrich
rank
ks
metric
appli
lethal
score
differ
lethal
score
mut
wildtyp
cell
shrna
determin
synthet
lethal
score
gene
repres
librari
tabl
signific
sl
interact
score
found
multipl
gene
pathway
p
p
p
fig
addit
gene
set
deriv
reactom
databas
contain
gene
essenti
pathway
activ
ie
enrich
expect
p
fisher
exact
test
supplement
tabl
use
gene
list
rank
synthet
lethal
score
perform
gene
set
enrich
analysi
gsea
subramanian
et
al
show
proteasom
pathway
kyoto
encyclopedia
gene
genom
kegg
ribosom
pathway
kegg
relat
translat
pathway
reactom
significantli
enrich
list
gene
rank
synthet
lethal
score
tabl
pathway
splice
also
enrich
p
fals
discoveri
rate
fdr
metaanalysi
three
data
set
synthet
lethal
activ
genet
screen
isogen
cancer
cell
line
allow
examin
phenotyp
effect
specif
genet
alter
otherwis
ident
genet
background
altern
approach
perform
rnai
screen
across
number
differ
cancer
cell
line
contextu
lethal
infer
compar
group
cancer
cell
line
classifi
accord
genet
alter
cowley
et
al
although
unsuit
analysi
effect
one
genet
determin
time
latter
method
repres
complementari
approach
use
isogen
cell
line
allow
test
reproduc
genotypespecif
vulner
within
differ
genet
context
cowley
et
al
therefor
perform
integr
analysi
data
sl
screen
isogen
cell
two
data
set
rnai
screen
perform
institut
panel
differ
cancer
cell
line
project
achil
data
set
rnai
screen
perform
cancer
cell
line
cheung
et
al
coltcanc
data
set
rnai
screen
cancer
cell
line
supplement
fig
koh
et
al
marcott
et
al
first
appli
atari
analyt
techniqu
assess
rnai
similar
achil
coltcanc
data
set
identifi
shrna
base
phenotyp
pattern
across
multipl
cell
line
like
affect
intend
target
gene
rel
offtarget
effect
shao
et
al
next
usng
atari
solut
quantif
phenotyp
effect
inhibit
gene
across
two
rnai
data
set
perform
twoclass
comparison
mut
wildtyp
cell
line
data
set
wilcoxon
test
see
materi
method
supplement
tabl
mut
cell
defin
cancer
cell
line
bear
oncogen
activ
mutat
wildtyp
cell
defin
cell
line
harbor
wildtyp
gene
also
mutat
amplif
kra
hra
nra
braf
pten
egfr
oncogen
supplement
tabl
confirm
analysi
identifi
gene
synthet
lethal
hyperactv
found
aktmtoractivationpathway
strongli
enrich
rnai
data
set
achil
data
set
enrich
coltcanc
data
set
enrich
supplement
tabl
neg
control
compar
cancer
cell
line
harbor
harbor
oncogen
kra
mutat
achil
data
set
comparison
deplet
kra
score
highli
signific
sl
expect
enrich
among
sl
gene
supplement
tabl
use
fisher
method
obtain
combin
pvalu
deriv
three
data
set
supplement
tabl
metaanalysi
result
enrich
rel
three
individu
analys
ie
analysi
screen
isogen
line
achil
data
set
analysi
figur
genomewid
shrna
screen
identifi
gene
synthet
lethal
oncogen
mutat
schemat
diagram
depict
experiment
procedur
use
genomewid
shrna
screen
isogen
mut
wildtyp
cell
line
pair
see
text
detail
b
graphic
distribut
dot
repres
singl
gene
present
genomewid
librari
gene
plot
contain
correspond
lethal
score
averag
among
shrna
target
gene
mut
wildtyp
cell
heat
map
legend
dot
also
color
accord
pvalu
synthet
lethal
mut
versu
wildtyp
cell
inset
within
graph
contain
three
top
enrich
nonredund
pathway
found
among
list
sl
gene
rank
sl
pvalu
see
also
supplement
tabl
coltcanc
data
set
analysi
fact
three
individu
analys
result
enrich
observ
versu
expect
combin
analys
result
enrich
p
fisher
exact
test
fig
supplement
tabl
result
highlight
util
perform
metaanalysi
includ
screen
perform
isogen
cell
line
parallel
screen
perform
multipl
cell
line
gsea
gene
list
rank
synthet
lethal
combin
pvalu
show
high
enrich
gene
implic
ribosometransl
enrich
top
proteasom
enrich
top
splice
pathway
enrich
top
fdr
three
pathway
supplement
tabl
importantli
enrich
score
gsea
es
gene
three
pathway
promin
combin
analysi
compar
analysi
screen
isogen
cell
line
cf
supplement
tabl
supplement
tabl
common
enrich
multipl
orthogon
screen
databas
three
pathway
strong
evid
involv
nononcogen
depend
tumor
activ
mutat
base
combin
analysi
design
focus
shrna
librari
shrna
per
gene
perform
secondari
screen
cell
line
analysi
secondari
screen
perform
fashion
similar
genomewid
screen
show
gene
target
librari
signific
sl
score
mut
cell
compar
wildtyp
cell
supplement
tabl
although
smaller
size
librari
compar
one
use
genomewid
screen
render
pathway
analysi
difficult
translat
proteasom
ribosom
pathway
significantli
enrich
fdr
corrobor
previou
find
examin
synthet
lethal
identifi
candid
pathway
perform
multicolor
competit
assay
mca
smogorzewska
et
al
gfpexpress
wildtyp
cell
dstomatoexpress
mut
cell
combin
cocultur
least
six
popul
doubl
absenc
presenc
drug
transduct
shrna
treatment
translat
elong
inhibitor
cycloheximid
chx
lactimidomycin
ltm
result
decreas
rel
surviv
mut
versu
wildtyp
cell
similar
observ
mtor
inhibitor
rapamycin
dual
inhibitor
fig
b
supplement
fig
cell
death
assay
stain
see
materi
method
reveal
chx
ltm
induc
significantli
cell
death
mut
versu
wildtyp
cell
fig
increas
cell
death
translat
inhibitor
mut
cell
versu
wildtyp
cell
higher
importantli
confirm
select
induct
cell
death
mut
versu
wildtyp
cell
chx
ltm
use
differ
pair
isogen
colon
tabl
c
enrich
plot
indic
pathway
deriv
gsea
list
gene
rank
combin
pvalu
synthet
lethal
mutat
supplement
tabl
cancer
cell
line
carri
differ
oncogen
mutat
fig
black
line
samuel
et
al
moreov
found
similar
effect
pten
cell
exhibit
pathway
activ
compar
wildtyp
counterpart
fig
supplement
fig
contrast
kra
mut
versu
wildtyp
cell
line
show
signific
differ
induct
cell
death
protein
synthesi
inhibit
well
mtor
signal
inhibit
supplement
fig
c
next
studi
effect
genet
inhibit
protein
translat
process
transduc
cell
lentivir
vector
express
doxycyclineinduc
shrna
target
translat
factor
score
top
hit
sl
gene
metaanalysi
three
data
set
supplement
tabl
mca
deplet
elong
factor
combin
pvalu
endogen
level
two
independ
shrna
result
signific
select
inhibit
mut
versu
wildtyp
cell
compar
two
neg
control
shrna
target
luciferas
fig
h
supplement
fig
deplet
ribosom
protein
p
similar
select
decreas
viabil
mut
compar
wildtyp
cell
addit
mca
combin
individu
shrna
target
increas
select
growth
inhibit
mut
cell
versu
wildtyp
compar
treatment
drug
shrna
individu
fig
result
collect
indic
pathway
activ
due
oncogen
mutat
pten
inactiv
confer
specif
suscept
ribosom
protein
translat
like
depend
mtor
addit
ribosometransl
pathway
proteasom
machineri
also
significantli
enrich
among
list
sl
hit
fig
investig
whether
express
compon
proteasom
pathway
upregul
respons
oncogen
activ
analyz
gene
express
profil
data
set
pten
pten
isogen
cancer
cell
line
data
set
gene
express
omnibu
geo
kim
et
al
data
set
contain
express
profil
parent
one
pten
control
clone
three
pten
clone
limmabas
analysi
ritchi
et
al
follow
gsea
show
multipl
compon
proteasom
upregul
pten
cell
compar
pten
fdr
fig
supplement
tabl
inde
proteasom
gene
contain
top
gene
rank
differenti
overexpress
pten
versu
pten
cell
result
enrich
expect
supplement
tabl
two
significantli
overexpress
gene
pten
versu
wildtyp
cell
geo
also
upregul
greater
twofold
mut
versu
wildtyp
cell
fig
supplement
fig
b
increas
mtordepend
sinc
express
gene
mut
cell
reduc
rapamycin
treatment
fig
supplement
fig
b
data
shown
upregul
proteasom
subunit
suggest
activ
proteasom
enhanc
mutant
therefor
analyz
proteasom
activ
mut
versu
wildtyp
cell
found
kinet
ubiquitin
conjug
degrad
protein
synthesi
inhibit
chx
significantli
faster
mut
wildtyp
cell
suggest
enhanc
rate
proteasomemedi
protein
degrad
mut
compar
wildtyp
cell
fig
addit
measur
chymotrypsinlik
activ
luciferasebas
report
assay
confirm
signific
increas
proteasom
activ
mut
versu
wildtyp
cell
fig
assess
synthet
lethal
proteasom
inhibit
mutat
use
pharmacolog
inhibit
treatment
cell
differ
inhibitor
proteasom
clastolactacystin
lalacton
bortezomib
result
select
inhibit
cell
growth
mut
versu
wildtyp
cell
fig
accompani
increas
cell
death
supplement
fig
similar
select
inhibit
found
pten
compar
pten
cell
supplement
fig
kra
mut
versu
kra
wildtyp
cell
supplement
fig
contrast
autophagi
inhibitor
bafilomycin
exhibit
select
effect
mut
cell
supplement
fig
data
indic
pathway
hyperactiv
result
increas
proteasom
activ
render
tumor
cell
sensit
proteasom
inhibit
rel
wildtyp
cell
pathway
hyperactiv
lead
increas
protein
turnov
increas
protein
synthesi
protein
degrad
reason
mut
pten
cell
sensit
translat
proteasom
inhibit
antagon
either
pathway
would
result
uncoupl
protein
synthesi
protein
degrad
therebi
impair
cell
surviv
via
effect
homeostasi
protein
turnov
support
fact
mca
use
simultan
translat
proteasom
inhibit
result
synergist
effect
cell
surviv
fig
fact
combin
inhibit
translat
proteasom
significantli
diminish
inhibit
either
pathway
alon
mut
versu
wildtyp
cell
fig
also
test
effect
bortezomib
tumor
growth
mice
subcutan
inject
wildtyp
mut
cell
flank
athym
nude
mice
wait
tumor
format
see
materi
method
mice
treat
either
vehicl
pb
mgkg
bortezomib
intraperiton
inject
daili
monitor
tumor
growth
found
although
wildtyp
mut
tumor
exhibit
respons
drug
mut
cell
tumor
show
significantli
stronger
respons
bortezomib
wildtyp
cell
tumor
fig
p
result
suggest
oncogen
mutat
tumor
promot
sensit
bortezomib
vivo
next
analyz
express
signatur
gene
pathway
found
synthet
lethal
h
cell
infect
indic
shrna
f
select
cultur
addit
presenc
absenc
doxycyclin
fac
analysi
perform
determin
fit
mut
cell
rel
wildtyp
b
analysi
perform
describ
mca
perform
treat
cell
differ
reagent
shrna
drug
individu
combin
use
concentr
nm
differ
combin
two
reagent
use
individu
two
reagent
use
individu
statist
signific
mutant
activ
human
primari
tumor
chose
analyz
cancer
genom
atla
tcga
gene
express
data
set
along
clinic
data
patient
colorect
carcinoma
sever
reason
screen
perform
isogen
human
colorect
cancer
cell
line
major
cell
line
use
twoclass
comparison
mut
wildtyp
line
achil
data
set
also
deriv
colorect
figur
percentag
mut
wildtyp
cell
end
assay
rel
treatment
dmso
shown
cll
clastolactacystin
lalacton
g
mca
perform
figur
treat
cell
differ
drug
singl
agent
combin
drug
use
nm
concentr
asterisk
refer
signific
differ
sampl
treat
chx
versu
chx
ltm
versu
ltm
h
wildtyp
mut
cell
inject
flank
nunu
nude
mice
tumor
format
mice
treat
vehicl
bortezomib
tumor
volum
monitor
chang
tumor
volum
time
wildtyp
mut
tumor
treat
vehicl
bortezomib
shown
pvalu
p
refer
comparison
chang
tumor
volum
bortezomibtr
vs
vehicletr
tumor
mut
wildtyp
tumor
wilcoxon
test
experi
repeat
twice
time
cohort
includ
least
seven
mice
cancer
oncogen
mutat
correl
higher
rate
recurr
wors
outcom
nonmetastat
colorect
cancer
et
al
ogino
et
al
order
compar
tumor
without
pathway
activ
sampl
first
classifi
accord
presenc
absenc
oncogen
mutat
andor
presenc
absenc
inactiv
mutat
delet
pten
addit
given
role
rtk
mutationamplif
promot
pathway
hyperactiv
tumor
mutat
amplif
egfr
classifi
among
tumor
pathway
activ
see
materi
method
limma
analysi
gene
express
follow
gsea
show
compon
ribosom
proteasom
pathway
significantli
enrich
tumor
pathway
activ
fdr
fig
sinc
oncogen
mutat
correl
wors
outcom
nonmetastat
colorect
cancer
et
al
ask
whether
gene
express
signatur
deriv
analysi
identifi
sl
gene
could
predict
surviv
patient
order
deriv
sl
signatur
colon
cancer
consid
metaanalysi
describ
select
gene
combin
pvalu
gene
deriv
averag
express
score
sl
gene
signatur
tumor
sampl
data
set
colorect
cancer
patient
compar
tumor
higher
lower
sl
gene
signatur
sl
gene
signatur
significantli
predict
surviv
among
colorect
cancer
patient
hr
p
fig
supplement
tabl
furthermor
analyz
patient
classifi
hyperactiv
describ
sl
gene
signatur
show
even
greater
abil
predict
overal
surviv
hr
p
fig
supplement
tabl
sl
gene
signatur
remain
signific
paramet
predict
surviv
take
consider
stage
age
site
diseas
fig
e
discoveri
synthet
lethal
highthroughput
rnai
screen
often
hinder
low
effici
reagent
offtarget
effect
heterogen
rnai
among
cancer
cell
line
hart
et
al
show
function
genom
approach
use
metaanalysi
perform
three
independ
screen
data
set
perform
differ
strategi
one
pair
isogen
cell
line
two
sever
differ
cancer
cell
line
differ
librari
superior
analysi
individu
data
set
detect
posit
control
gene
case
known
tabl
surviv
analysi
kaplanmei
curv
compar
colorect
cancer
patient
tcga
data
high
low
sl
signatur
score
top
bottom
half
colorect
tumor
supplement
tabl
subset
tumor
hyperact
pathway
supplement
tabl
hr
pvalu
wald
test
shown
e
tabl
show
hr
pvalu
multivari
cox
proport
hazard
model
includ
sl
signatur
clinic
covari
colorect
cancer
patient
subset
hyperact
pathway
e
synthet
lethal
critic
player
pathway
suggest
sl
gene
identifi
metaanalysi
like
higher
confid
greater
potenc
identifi
individu
screen
analysi
identifi
novel
vulner
cancer
cell
harbor
pathway
activ
two
major
pathway
combin
analysi
identifi
sl
oncogen
pathway
activ
ribosometransl
proteasom
pathway
protein
synthesi
enhanc
modul
activ
mtor
pathway
hay
sonenberg
data
suggest
mutat
also
enhanc
protein
degrad
proteasom
find
consist
recent
studi
suggest
mtor
activ
consequ
increas
protein
synthesi
lead
concomit
increas
protein
degrad
promot
mainten
cellular
amino
acid
homeostasi
zhang
et
al
true
would
predict
uncoupl
ribosom
protein
synthesi
proteasom
protein
degrad
via
inhibit
either
pathway
pathway
simultan
would
compromis
cell
viabilityparticularli
context
mtor
activ
hypothesi
agreement
data
show
simultan
proteasom
translat
inhibit
synergist
effect
actual
diminish
vulner
inhibit
either
pathway
alon
despit
increas
interest
explor
protein
synthesi
inhibit
therapeut
strategi
cancer
approach
yet
use
clinic
mainli
due
pharmacokinet
barrier
toxic
exist
drug
hsieh
et
al
malina
et
al
interestingli
inhibit
capdepend
translat
block
bind
nascent
mrna
transcript
improv
respons
chemotherapi
murin
model
eumyc
lymphoma
cencic
et
al
contrast
target
proteasom
alreadi
emerg
viabl
strategi
type
malign
adam
bortezomib
velcad
approv
treatment
patient
multipl
myeloma
mantl
cell
lymphoma
http
wwwfda
gov
solid
tumor
number
clinic
trial
perform
patient
advanc
usual
metastat
tumor
show
signific
benefit
treatment
bortezomib
singl
agent
shah
et
al
yang
et
al
among
mani
potenti
reason
inefficaci
trial
dose
use
trial
advanc
stage
diseas
treatment
bortezomib
singl
agent
furthermor
select
patient
clinic
trial
base
tumor
molecular
marker
may
predict
respons
specif
agent
crucial
aspect
new
clinic
trial
target
therapi
data
indic
presenc
oncogen
mutat
might
confer
particular
suscept
proteasom
inhibitor
addit
data
suggest
express
level
proteasom
factor
might
also
repres
use
molecular
biomark
identifi
patient
may
benefit
treatment
proteasom
inhibitor
relev
analysi
sl
tumor
hyperact
pathway
cancer
patient
highlight
surviv
analysi
colorect
cancer
patient
among
patient
hyperact
gene
express
signatur
deriv
sl
hit
colon
cancer
cell
line
significantli
correl
surviv
word
patient
hyperact
show
lower
express
gene
defin
signatur
better
surviv
importantli
express
signatur
signific
predictor
surviv
also
multivari
analysi
take
account
stage
diseas
result
highlight
fact
sl
gene
identifi
analysi
also
like
repres
bona
fide
sl
factor
human
tumor
find
may
also
relev
wildtyp
tumor
harbor
genet
epigenet
alter
result
akt
mtor
pathway
activ
thu
sl
factor
may
repres
biomark
predict
patient
outcom
also
potenti
therapeut
target
shrna
genomewid
librari
shrna
construct
shrna
librari
target
human
gene
four
shrna
per
gene
clone
retrovir
mscv
vector
mut
wildtyp
cell
infect
moi
multipl
infect
select
puromycin
passag
eight
popul
doubl
cell
harvest
right
select
start
popul
eight
popul
doubl
end
popul
rel
distribut
shrna
cell
popul
determin
ng
pcramplifi
halfhairpin
schlabach
et
al
briefli
ng
dna
harvest
cell
standard
procedur
halfhairpin
amplifi
pcr
index
primer
final
ad
pcr
amplif
illumina
sequenc
screen
perform
triplic
transduct
individu
shrna
target
specif
gene
secondari
shrna
screen
shrna
clone
lentivir
vector
cell
cultur
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
fb
penicillinstrepomycin
mm
glutamin
viru
product
cell
transfect
use
transit
minu
supernat
harvest
h
store
infect
cell
expos
appropri
amount
viru
h
presenc
polybren
shrna
screen
cell
infect
moi
protein
gel
western
blot
run
use
standard
procedur
protein
detect
use
licor
system
licor
bioscienc
transfer
nitrocellulos
membran
block
min
odyssey
block
buffer
contain
pb
tween
incub
overnight
buffer
contain
pb
specif
primari
antibodi
wash
pb
tween
incub
alexa
fluorconjug
secondari
antibodi
invitrogen
second
wash
pb
tween
signal
detect
licor
system
quantifi
use
imag
studio
softwar
licor
bioscienc
qpcr
total
rna
isol
use
rnaeasi
minikit
qiagen
cdna
synthes
use
high
capac
rnatocdna
kit
invitrogen
accord
manufactur
instruct
rtqpcr
perform
triplic
use
gene
express
assay
appli
biosystem
appli
biosystem
fast
machin
gapdh
actb
use
intern
control
normal
rel
quantif
data
analysi
shrna
screen
cell
line
sequenc
read
align
perform
use
bowti
softwar
langmead
et
al
edger
use
estim
lethal
score
mut
wildtyp
cell
line
robinson
et
al
shrna
read
count
least
one
replic
consid
neg
binomi
distribut
edger
classic
method
use
determin
signific
rel
represent
shrna
end
start
popul
lethal
score
shrna
defin
log
pvalu
multipli
sign
correspond
direct
fold
chang
gene
increas
start
end
popul
opposit
behavior
thu
posit
lethal
score
correspond
shrna
undergo
signific
drop
start
end
popul
vice
versa
neg
lethal
score
fig
supplement
fig
afterward
riger
ks
metric
appli
lethal
score
mut
wildtyp
cell
shrna
determin
synthet
lethal
score
gene
librari
lethal
score
repres
differ
lethal
score
mut
versu
wildtyp
cell
appli
atari
achil
coltcanc
data
set
marcott
et
al
next
use
atari
solut
quantif
phenotyp
effect
inhibit
gene
across
two
rnai
data
set
perform
twoclass
comparison
kra
mut
kra
wildtyp
cell
line
data
set
wilcoxon
test
synthet
lethal
mut
cell
defin
cancer
cell
line
bear
oncogen
activ
mutat
wildtyp
cell
defin
cell
line
wildtyp
gene
also
mutat
amplif
kra
hra
nra
braf
pten
egfr
oncogen
similarli
kra
synthet
lethal
kra
mutant
cell
defin
cancer
cell
line
bear
oncogen
activ
kra
mutat
wildtyp
cell
defin
cell
line
wildtyp
kra
gene
also
mutat
amplif
kra
hra
nra
braf
egfr
oncogen
list
cell
line
use
comparison
supplement
tabl
fisher
method
use
obtain
combin
pvalu
pvalu
deriv
individu
analys
screen
isogen
cell
line
achil
data
set
coltcanc
data
set
qvalu
determin
use
benjaminihochberg
method
see
also
supplement
tabl
cell
death
assay
fluoresc
dna
intercal
commonli
use
stain
dead
cell
briefli
cell
plate
well
plate
next
day
cell
treat
drug
test
solvent
h
cell
wash
twice
pb
trypsin
cell
well
resuspend
pb
contain
stain
solut
gml
bd
boscienc
incub
min
dark
prior
fac
analysi
presenc
asterisk
figur
panel
rel
cell
death
assay
indic
statist
signific
differ
cell
death
rate
mut
wildtyp
correspond
experiment
condit
comparison
pten
pten
use
geo
data
set
kim
et
al
gene
calcul
pvalu
overexpress
pten
cell
versu
pten
use
onesid
ttest
supplement
tabl
gsea
perform
standalon
softwar
avail
http
wwwbroadinstituteorggseaindex
jsp
use
classic
method
subramanian
et
al
use
tcga
data
set
gene
express
data
agil
microarray
data
set
andor
rna
sequenc
rnaseq
data
gene
mutat
copi
number
variat
nonmetastat
colorect
tumor
sampl
http
gdacbroadinstituteorg
tumor
sampl
function
relev
mutat
pten
delet
pten
amplif
overexpress
egfr
classifi
hyperact
pathway
tumor
normal
paramet
consid
wild
type
pathway
limmabas
analysi
ritchi
et
al
perform
compar
hyperact
versu
wildtyp
tumor
sl
gene
express
signatur
deriv
sl
gene
list
combin
analysi
three
data
set
supplement
tabl
includ
gene
combin
pvalu
gene
surviv
analysi
univari
multivari
cox
proport
hazard
model
use
determin
impact
paramet
overal
surviv
wald
test
pvalu
report
follow
chemic
use
cayman
chemic
cayman
chemic
ltm
millipor
chx
sigmaaldrich
rapamycin
sigmaaldrich
cayman
chemic
emd
millipor
clastolactacystin
lalacton
sigma
epoxomicin
sigma
bortezomib
selleckchem
doxycyclin
fisher
follow
antibodi
use
ubiquitin
antibodi
clone
enzo
life
scienc
antibodi
sigma
antibodi
novu
biolog
antibodi
abcam
actin
antibodi
santa
cruz
biotechnolog
competit
assay
use
test
candid
genesdrug
signal
pathway
inhibitor
screen
modifi
previou
protocol
smogorzewska
et
al
carri
plate
independ
triplic
assay
gfplabel
mut
dstomatolabel
wildtyp
cell
mix
seed
ratio
well
altern
gfpand
dstomatolabel
cell
gfplabel
mut
unlabel
wildtyp
cell
vice
versa
use
cell
treat
drug
dmso
control
prior
fac
analysi
fit
mut
cell
rel
wild
type
determin
end
assay
ratio
percentag
mut
cell
sampl
treat
drug
shrna
see
percentag
mut
cell
sampl
treat
dmso
control
shrna
figur
eg
fig
concentr
nm
drug
correspond
dmso
control
treatment
presenc
asterisk
figur
panel
rel
mca
indic
statist
signific
differ
fit
mut
cell
treatment
sampl
drug
shrna
compar
control
sampl
dmso
control
shrna
deriv
use
wilcoxon
test
shrnabas
mca
shrna
design
synthes
clonabl
pcr
product
clone
induc
lentivir
vector
supplement
tabl
cell
transduc
vector
express
shrna
select
cultur
presenc
absenc
doxycyclin
addit
fac
analysi
perform
use
bd
facsaria
ii
bd
bioscienc
mca
perform
describ
compar
sampl
treat
shrna
specif
gene
interest
sampl
treat
shrna
specif
luciferas
measur
proteasom
activ
carri
use
promega
proteasomeglo
chymotrypsinlik
cellbas
assay
proteasomeglo
cellbas
assay
homogen
luminesc
assay
individu
measur
chymotrypsinlik
trypsinlik
caspaselik
proteas
activ
associ
proteasom
complex
cultur
cell
briefli
appropri
substrat
inhibitor
ad
proteasomeglo
cellbas
reagent
incub
room
temperatur
min
equilibr
equal
volum
reagent
ad
drugtreat
cell
plate
shaken
luminesc
read
min
incub
effect
bortezomib
tumor
growth
mice
nunu
mice
purchas
charl
river
laboratori
intern
inc
wildtyp
mut
cell
line
detect
pathogenfre
charl
river
laboratori
intern
inc
cultur
fb
penicillinstreptomycin
cell
resuspend
serumfre
medium
mix
equal
amount
matrigel
bd
bioscienc
mice
inject
million
cell
per
shot
two
locat
per
mous
flank
mice
randomli
group
treatment
start
tumor
size
reach
mm
experi
repeat
twice
everi
time
cohort
includ
least
seven
mice
tumor
size
monitor
weekli
volum
calcul
follow
formula
mm
length
width
width
